Search
Biotech CEO Sisterhood: Deborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into a position of leadership
Interviewed by Sisterhood editorial board member Erika Smith, Deborah Dunsire describes her career path, how medicine is making progress...
Dec 5, 2024
BioVenture VoiCes Episode 7: MPM BioImpact's Ansbert Gadicke
MPM's founder and managing partner discusses the firm's 30+ years of investing in life sciences, including the philosophy of placing...
Dec 2, 2024
The Co-Founder and CTO of Seoul based Organoid Sciences walks us through how the company is using organoids for regenerative medicine, CRO services, and precision medicine
KyungJin Lee explains how Organoid Sciences is turning its expertise in organoids into a diversified business, and how it has been...
Nov 28, 2024
The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring
CEO Jame Lee, a founder of multiple biotech companies, describes the operational experience that he suggests is a key differentiator for...
Nov 27, 2024
Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines
Founder and CEO Seulki Lee describes his training in science, part of which was working on GLP-1s years ago, and the founding of the...
Nov 26, 2024
BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans
He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put...
Nov 25, 2024
Led by a longtime leader of Korea's biotech sector, GI Innovation has science-forward programs such as fusion proteins that aim to redefine IL-2 and an IgE trap that could go up against Xolair
BG Rhee walks us through GI Innovation's programs and describes what he would like to see improve about Korea's biotech sector, including...
Nov 25, 2024
Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies
V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint,...
Nov 25, 2024
With an experienced researcher at the helm, Seoul-based Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies
CEO Soon Paik, who was a developer Oncotype Dx and the founding director of Samsung Cancer Research Institute, discusses Theragen's...
Nov 24, 2024
London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting
Michael McElhaugh describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen,...
Nov 22, 2024
London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections
CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA...
Nov 22, 2024
Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well
Founder & CEO Sang Hoon Lee describes the science that sets ABL apart and where he sees Korea biotech headed.
Nov 22, 2024
Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea
He explains the power of protein degradation, and the upside to Orum's targeted delivery approach. Plus, selling an asset to Bristol...
Nov 22, 2024
London Healthcare Week: A discussion on treating neurodegenerative diseases with the CEO of AC Immune
Andrea Pfeifer describes the rationale for treating neurodegenerative disease with immunotherapies, and the importance of treating people...
Nov 22, 2024
London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space
Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major...
Nov 21, 2024
The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and Hôpital Beaujon Professor of...
Nov 21, 2024
From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi
CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced...
Nov 21, 2024
Visiting the largest cell therapy company in Korea, GC Cell, and learning about its approved immunotherapy for hepatocellular carcinoma, its CAR-NK programs in development, and more
CEO James Park describes GC Cell's history, its approved cell therapy that has been on the market in Korea since 2007, and its programs...
Nov 21, 2024
London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program
CEO Amy Burroughs walks us through what the company saw in the obesity program, and previews what to expect from initial cohorts in CML...
Nov 21, 2024
London Healthcare Week: Forbion Managing Partner Sander Slootweg shares his thoughts on the year ahead, the IPO market, M&A environment, areas of interest, and more
Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and...
Nov 20, 2024
.png){kind=logo}
